Nicholas O Davidson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8696696/publications.pdf

Version: 2024-02-01

80	2,732	218381	189595
papers	citations	26 h-index	50 g-index

82	82	82	3228
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Validation of the Dallas Steatosis Index to Predict Nonalcoholic Fatty Liver Disease in the UK Biobank Population. Clinical Gastroenterology and Hepatology, 2022, 20, 2638-2640.	2.4	5
2	Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles. Hepatology, 2022, 76, 1121-1134.	3.6	31
3	Liver-specific deletion of Mttp versus Tm6sf2 reveals distinct defects in stepwise VLDL assembly. Journal of Lipid Research, 2021, 62, 100080.	2.0	3
4	Apobec1 complementation factor overexpression promotes hepatic steatosis, fibrosis, and hepatocellular cancer. Journal of Clinical Investigation, 2021, 131, .	3.9	21
5	Ceramide Salvage, Gut Mucosal Immunoglobulin A Signaling, and Dietâ€Induced NASH. Hepatology, 2021, 73, 884-886.	3.6	1
6	Increased Risk of Advanced Colonic Adenomas and Timing of Surveillance Colonoscopy Following Solid Organ Transplantation. Digestive Diseases and Sciences, 2021, , 1.	1.1	2
7	Liverâ€Specific Deletion of Mouse Tm6sf2 Promotes Steatosis, Fibrosis, and Hepatocellular Cancer. Hepatology, 2021, 74, 1203-1219.	3.6	57
8	APOBEC1 mediated C-to-U RNA editing: target sequence and trans-acting factor contribution to 177 RNA editing events in 119 murine transcripts in vivo. Rna, 2021, 27, 876-890.	1.6	8
9	Dysregulation of mannose-6-phosphateâ€“dependent cholesterol homeostasis in acinar cells mediates pancreatitis. Journal of Clinical Investigation, 2021, 131, .	3.9	9
10	Inhibition of chylomicron assembly leads to dissociation of hepatic steatosis from inflammation and fibrosis. Journal of Lipid Research, 2021, 62, 100123.	2.0	3
11	Increased Adiposity and Reduced Lean Body Mass in Patients with Short Bowel Syndrome. Digestive Diseases and Sciences, 2020, 65, 3271-3279.	1.1	6
12	Derivation and Internal Validation of a Clinical Prediction Tool to Predict Nonalcoholic Fatty Liver Disease in Patients With Crohnâ€™s Disease. Inflammatory Bowel Diseases, 2020, 26, 1917-1925.	0.9	11
13	Opening ASBMB publications freely to all. Journal of Biological Chemistry, 2020, 295, 7814-7815.	1.6	1
14	Opening ASBMB publications freely to all. Molecular and Cellular Proteomics, 2020, 19, 914-915.	2.5	1
15	Genetic Pathways in Nonalcoholic Fatty Liver Disease: Insights From Systems Biology. Hepatology, 2020, 72, 330-346.	3.6	75
16	Bile Acid Diarrhea and NAFLD: Shared Pathways for Distinct Phenotypes. Hepatology Communications, 2020, 4, 493-503.	2.0	13
17	The data must be accessible to all. Journal of Biological Chemistry, 2020, 295, 4371.	1.6	3
18	The Data Must Be Accessible to All. Molecular and Cellular Proteomics, 2020, 19, 569-570.	2.5	2

#	Article	IF	Citations
19	Stem cell and niche regulation in human short bowel syndrome. JCI Insight, 2020, 5, .	2.3	7
20	Myeloid-specific Asxl2 deletion limits diet-induced obesity by regulating energy expenditure. Journal of Clinical Investigation, 2020, 130, 2644-2656.	3.9	13
21	The data must be accessible to all. Journal of Lipid Research, 2020, 61, 465.	2.0	1
22	Opening ASBMB publications freely to all. Journal of Lipid Research, 2020, 61, 969-970.	2.0	0
23	Crohnâ€™s Disease Is Associated With an Increased Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study Using Magnetic Resonance Proton Density Fat Fraction Mapping. Clinical Gastroenterology and Hepatology, 2019, 17, 2816-2818.	2.4	19
24	Impaired Chylomicron Assembly Modifies Hepatic Metabolism Through Bile Acidâ€“Dependent and Transmissible Microbial Adaptations. Hepatology, 2019, 70, 1168-1184.	3.6	12
25	Building bridges: PCSK7 as a NAFLD candidate gene connecting hepatic inflammation with hypertriglyceridemia. Journal of Lipid Research, 2019, 60, 1067-1068.	2.0	0
26	Missense Mutant Patatinâ€Like Phospholipase Domain Containing 3 Alters Lipid Droplet Turnover in Partnership With CGIâ€58. Hepatology, 2019, 69, 2323-2325.	3.6	2
27	Influence of Crohnâ€™s disease related polymorphisms in innate immune function on ileal microbiome. PLoS ONE, 2019, 14, e0213108.	1.1	13
28	Dropping in on Lipid Mobilization From the Gut. Cellular and Molecular Gastroenterology and Hepatology, 2019, 7, 291-292.	2.3	0
29	Hepatocyte and stellate cell deletion of liver fatty acid binding protein reveals distinct roles in fibrogenic injury. FASEB Journal, 2019, 33, 4610-4625.	0.2	21
30	Apobec1 complementation factor (A1CF) and RBM47 interact in tissue-specific regulation of C to U RNA editing in mouse intestine and liver. Rna, 2019, 25, 70-81.	1.6	39
31	Tieâ€ing Up Angiogenesis to Treat Nonalcoholic Steatohepatitis. Hepatology, 2019, 69, 937-939.	3.6	1
32	Perilipin 5 and liver fatty acid binding protein function to restore quiescence in mouse hepatic stellate cells. Journal of Lipid Research, 2018, 59, 416-428.	2.0	16
33	Genetic Regulation of Intestinal Lipid Transport and Metabolism. , 2018, , 1109-1131.		1
34	Cd36 knockout mice are protected against lithogenic diet-induced gallstones. Journal of Lipid Research, 2017, 58, 1692-1701.	2.0	13
35	Prevention of hepatic fibrosis with liver microsomal triglyceride transfer protein deletion in liver fatty acid binding protein null mice. Hepatology, 2017, 65, 836-852.	3.6	22
36	How to Prepare for and Write a Grant: Personal Perspectives. Gastroenterology, 2017, 152, 7-11.	0.6	4

#	Article	IF	Citations
37	Parent-of-origin effects of A1CF and AGO2 on testicular germ-cell tumors, testicular abnormalities, and fertilization bias. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E5425-33.	3.3	18
38	RNA Editing: Another Level of Somatic Mutagenic Activity in Gastric Cancer. Gastroenterology, 2016, 151, 584-587.	0.6	1
39	A trimming-and-retrieving alignment scheme for reduced representation bisulfite sequencing: Fig. 1.. Bioinformatics, 2015, 31, 2040-2042.	1.8	3
40	Genome-wide identification and functional analysis of Apobec-1-mediated C-to-U RNA editing in mouse small intestine and liver. Genome Biology, 2014, 15, R79.	13.9	87
41	Reassessment of murine APOBEC1 as a retrovirus restriction factor in vivo. Virology, 2014, 468-470, 601-608.	1.1	16
42	Liver Fatty Acid-Binding Protein (L-Fabp) Modifies Intestinal Fatty Acid Composition and Adenoma Formation in ApcMin/+ Mice. Cancer Prevention Research, 2013, 6, 1026-1037.	0.7	19
43	Transgenerational epigenetic effects of the Apobec1 cytidine deaminase deficiency on testicular germ cell tumor susceptibility and embryonic viability. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, E2766-73.	3.3	50
44	Grant Writing: Tips and Pointers From a Personal Perspective. Gastroenterology, 2012, 142, 4-7.	0.6	8
45	Intestine-Specific Mttp Deletion Decreases Mortality and Prevents Sepsis-Induced Intestinal Injury in a Murine Model of Pseudomonas aeruginosa Pneumonia. PLoS ONE, 2012, 7, e49159.	1.1	20
46	MicroRNAs and liver disease. Translational Research, 2011, 157, 241-252.	2.2	94
47	Mouse and Other Rodent Models of C to U RNA Editing. Methods in Molecular Biology, 2011, 718, 121-135.	0.4	10
48	Therapeutic RNA manipulation in liver disease. Hepatology, 2010, 51, 1055-1061.	3.6	27
49	APOBECâ€1â€mediated RNA editing. Wiley Interdisciplinary Reviews: Systems Biology and Medicine, 2010, 2, 594-602.	6.6	100
50	Apobec-1 Complementation Factor Modulates Liver Regeneration by Post-transcriptional Regulation of Interleukin-6 mRNA Stability. Journal of Biological Chemistry, 2010, 285, 19184-19192.	1.6	25
51	Decreased Expression of Cholesterol 7Î±-Hydroxylase and Altered Bile Acid Metabolism in Apobec-1â^'/â^' Mice Lead to Increased Gallstone Susceptibility. Journal of Biological Chemistry, 2009, 284, 16860-16871.	1.6	19
52	Diet-induced alterations in intestinal and extrahepatic lipid metabolism in liver fatty acid binding protein knockout mice. Molecular and Cellular Biochemistry, 2009, 326, 79-86.	1.4	37
53	Altered hepatic triglyceride content after partial hepatectomy without impaired liver regeneration in multiple murine genetic models. Hepatology, 2008, 48, 1097-1105.	3.6	101
54	Translational approaches to addressing complex genetic pathways in colorectal cancer. Translational Research, 2008, 151, 10-16.	2.2	13

#	Article	IF	Citations
55	Conditional Intestinal Lipotoxicity in Apobec-1-/- Mttp-IKO Mice. Journal of Biological Chemistry, 2007, 282, 33043-33051.	1.6	28
56	Mouse Models as Tools to Explore Cytidine-to-Uridine RNA Editing. Methods in Enzymology, 2007, 424, 417-435.	0.4	4
57	Deletion of the AU-Rich RNA Binding Protein Apobec-1 Reduces Intestinal Tumor Burden in Apcmin Mice. Cancer Research, 2007, 67, 8565-8573.	0.4	40
58	Genetic testing in colorectal cancer: who, when, how and why. Keio Journal of Medicine, 2007, 56, 14-20.	0.5	25
59	Targeted Deletion of the Murine apobec-1 Complementation Factor (acf) Gene Results in Embryonic Lethality. Molecular and Cellular Biology, 2005, 25, 7260-7269.	1.1	51
60	Grant writing and academic survival: what the fellow needs to know. Gastrointestinal Endoscopy, 2005, 61, 726-727.	0.5	4
61	Apobec-1 protects intestine from radiation injury through posttranscriptional regulation of cyclooxygenase-2 expression. Gastroenterology, 2004, 127, 1139-1149.	0.6	42
62	C-to-U RNA Editing: Mechanisms Leading to Genetic Diversity. Journal of Biological Chemistry, 2003, 278, 1395-1398.	1.6	131
63	Thyroid Hormone Regulates Hepatic Triglyceride Mobilization and Apolipoprotein B Messenger Ribonucleic Acid Editing in a Murine Model of Congenital Hypothyroidism. Endocrinology, 2003, 144, 711-719.	1.4	29
64	Molecular Regulation, Evolutionary, and Functional Adaptations Associated with C to U Editing of Mammalian ApolipoproteinB mRNA. Progress in Molecular Biology and Translational Science, 2003, 75, 1-41.	1.9	22
65	Câ†'U Editing of Neurofibromatosis 1 mRNA Occurs in Tumors That Express Both the Type II Transcript and apobec-1, the Catalytic Subunit of the Apolipoprotein B mRNAâ€"Editing Enzyme. American Journal of Human Genetics, 2002, 70, 38-50.	2.6	67
66	The challenge of target sequence specificity in Câ†'U RNA editing. Journal of Clinical Investigation, 2002, 109, 291-294.	3.9	15
67	Mutagenesis of Apobec-1 Complementation Factor Reveals Distinct Domains That Modulate RNA Binding, Protein-Protein Interaction with Apobec-1, and Complementation of C to U RNA-editing Activity. Journal of Biological Chemistry, 2001, 276, 46386-46393.	1.6	51
68	Novel Role for RNA-binding Protein CUGBP2 in Mammalian RNA Editing. Journal of Biological Chemistry, 2001, 276, 47338-47351.	1.6	91
69	Ã"â€–Identification of GRY-RBP as an Apolipoprotein B RNA-binding Protein That Interacts with Both Apobec-1 and Apobec-1 Complementation Factor to Modulate C to U Editing. Journal of Biological Chemistry, 2001, 276, 10272-10283.	1.6	90
70	Escherichia coli sepsis increases hepatic apolipoprotein B secretion by inhibiting degradation. Lipids, 2000, 35, 1079-1086.	0.7	17
71	An AU-Rich Sequence Element (UUUN[A/U]U) Downstream of the Edited C in Apolipoprotein B mRNA Is a High-Affinity Binding Site for Apobec-1: Binding of Apobec-1 to This Motif in the 3â€² Untranslated Region of c- myc Increases mRNA Stability. Molecular and Cellular Biology, 2000, 20, 1982-1992.	1.1	87
72	APOLIPOPROTEINB: mRNA Editing, Lipoprotein Assembly, and Presecretory Degradation. Annual Review of Nutrition, 2000, 20, 169-193.	4.3	270

#	Article	IF	Citations
73	A mouse model of human familial hypercholesterolemia: Markedly elevated low density lipoprotein cholesterol levels and severe atherosclerosis on a low-fat chow diet. Nature Medicine, 1998, 4, 934-938.	15.2	209
74	Apolipoprotein B mRNA Editing Is Preserved in the Intestine and Liver of Zinc-Deficient Rats. Journal of Nutrition, 1996, 126, 860-864.	1.3	11
75	Increased hepatic synthesis and accumulation of plasma apolipoprotein B100 in copper-deficient rats does not result from modification in apolipoprotein B mRNA editing. Lipids, 1996, 31, 433-436.	0.7	7
76	Hepatic Expression of the Catalytic Subunit of the Apolipoprotein B mRNA Editing Enzyme (apobec-1) Ameliorates Hypercholesterolemia in LDL Receptor-Deficient Rabbits. Human Gene Therapy, 1996, 7, 943-957.	1.4	62
77	Targeted Disruption of the Mouse apobec-1 Gene Abolishes Apolipoprotein B mRNA Editing and Eliminates Apolipoprotein B48. Journal of Biological Chemistry, 1996, 271, 9887-9890.	1.6	131
78	Molecular cloning of a human small intestinal apolipoprotein B mRNA editing protein. Nucleic Acids Research, 1994, 22, 1874-1879.	6.5	82
79	Apolipoprotein B mRNA Editing: A Key Controlling Element Targeting Fats to Proper Tissue. Annals of Medicine, 1993, 25, 539-543.	1.5	33
80	Apolipoprotein B messenger RNA editing is developmentally regulated in pig small intestine: Nucleotide comparison of apolipoprotein B editing regions in five species. Biochemical and Biophysical Research Communications, 1990, 173, 74-80.	1.0	46